Chronic viral hepatitis is defined as inflammation of the liver tissue persisting for longer than six months, caused primarily by hepatotropic viruses. The condition falls under ICD-10 code B18 and ICD-11 code 1E50. While acute hepatitis may resolve spontaneously or progress to chronic disease, chronic viral hepatitis represents a sustained infectious process that distinguishes it from other etiologies of hepatic inflammation such as alcohol-related, drug-induced, or autoimmune hepatitis.
Disease Profile
Chronic viral hepatitis
慢性病毒性肝炎
Chronic viral hepatitis represents a persistent inflammatory condition of the liver lasting beyond six months, most commonly caused by hepatitis B and C viruses, though hepatitis D and E may also contribute to chronic disease in specific epidemiological contexts. The condition poses substantial global health burdens through progressive liver damage, including cirrhosis, hepatic failure, and hepatocellular carcinoma. Surveillance systems must account for the often-asymptomatic nature of early chronic infection and the variable clinical trajectories across different viral etiologies.
Chronic viral hepatitis presents along a broad clinical spectrum, ranging from completely asymptomatic infection in early stages to overt constitutional symptoms including fatigue, nausea, vomiting, poor appetite, and joint pain as inflammation progresses. Jaundice may occur but typically appears late in the disease course, often signaling advanced hepatic dysfunction. The chronic inflammatory state may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer over years to decades. Some individuals remain asymptomatic for extended periods, with diagnosis occurring incidentally through routine laboratory screening or evaluation of non-specific symptoms.
Source-backed epidemiological detail for chronic viral hepatitis specifically is not yet available. However, hepatitis viruses A, B, C, D, and E collectively represent the most common infectious causes of hepatitis globally. The Wikipedia source indicates that hepatitis B is mainly sexually transmitted but may also pass from mother to child during pregnancy or childbirth and spread through infected blood, while hepatitis C is commonly spread through infected blood such as during needle sharing among intravenous drug users. Hepatitis D can only infect individuals already infected with hepatitis B, creating a dependent epidemiological relationship between these two viruses.
Transmission pathways vary by viral agent within the chronic viral hepatitis spectrum. Hepatitis B is primarily transmitted through sexual contact, mother-to-child routes during pregnancy or childbirth, and exposure to infected blood. Hepatitis C spreads predominantly through blood-borne exposure, with needle sharing among intravenous drug users representing a common transmission scenario. Hepatitis A and E are mainly spread through contaminated food and water, though chronic outcomes from these infections appear less common in immunocompetent adults. Hepatitis D requires concurrent hepatitis B infection for its replication, making its transmission contingent upon hepatitis B exposure.
Risk groups for chronic viral hepatitis acquisition vary by viral etiology. Intravenous drug users face elevated hepatitis C risk through blood-borne transmission associated with needle sharing. Sexually active populations may acquire hepatitis B through sexual contact, with additional risk during pregnancy and childbirth for vertical transmission to infants. Healthcare workers experience occupational exposure risk through potential blood contact. Individuals already infected with hepatitis B face the additional threat of hepatitis D superinfection, which can accelerate disease progression. Source-backed detail on specific high-risk demographic groups for chronic viral hepatitis is not yet available.
Prevention strategies for chronic viral hepatitis include vaccination against hepatitis A and B for susceptible populations, particularly those at elevated exposure risk. Food and water safety measures help prevent hepatitis A and E transmission. Blood safety protocols, including screening of blood products and sterile medical equipment practices, reduce blood-borne transmission of hepatitis B and C. Harm reduction programs targeting intravenous drug users, such as needle exchange initiatives, address a key transmission pathway for hepatitis C. The Wikipedia source indicates that hepatitis D prevention is inherently linked to hepatitis B prevention measures.
Surveillance for chronic viral hepatitis must account for the frequently asymptomatic nature of early infection, which may delay diagnosis and undercount true disease burden. Laboratory indicators such as elevated liver enzymes and viral serology serve as primary screening tools. The chronicity criterion of persistence beyond six months requires longitudinal observation rather than acute event capture. Monitoring should consider the potential for disease progression to cirrhosis, liver failure, and hepatocellular carcinoma as downstream complications. Different viral etiologies may warrant distinct surveillance approaches given their varying transmission dynamics and population distributions.
- B18
- 1E50
Dataset Archive
Supplementary Data | Multi-country disease dataset
Machine-readable multi-country disease dataset (JSON/CSV) with source metadata.
Suggested presentation pattern: cite the data version and coverage window when exporting charts or tables for publication.